This gene therapy has record $4.25 million price. It's saved children.

AdobeEverymorning,VictoriaRasberrygetsupbefore6a.m.,walkstothebedroomdownthehall,andhelpsher8-year-o AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli




comprehensive

author：comprehensive    Page View：6545
Adobe

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

advertisement

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Readout Newsletter: Illumina, CRISPR, Regeneron
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban